CA2135499A1 - Methode et reagent pour l'inhibition de la cancerogenese - Google Patents
Methode et reagent pour l'inhibition de la cancerogeneseInfo
- Publication number
- CA2135499A1 CA2135499A1 CA002135499A CA2135499A CA2135499A1 CA 2135499 A1 CA2135499 A1 CA 2135499A1 CA 002135499 A CA002135499 A CA 002135499A CA 2135499 A CA2135499 A CA 2135499A CA 2135499 A1 CA2135499 A1 CA 2135499A1
- Authority
- CA
- Canada
- Prior art keywords
- ribozyme
- rna molecule
- cell
- mrna
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/123—Hepatitis delta
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88282292A | 1992-05-14 | 1992-05-14 | |
US88288592A | 1992-05-14 | 1992-05-14 | |
US93642292A | 1992-08-26 | 1992-08-26 | |
US93653192A | 1992-08-26 | 1992-08-26 | |
US07/936,421 US5750390A (en) | 1992-08-26 | 1992-08-26 | Method and reagent for treatment of diseases caused by expression of the bcl-2 gene |
US07/936,532 US6492512B1 (en) | 1992-08-26 | 1992-08-26 | Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression |
US07/936,110 US5610052A (en) | 1992-08-26 | 1992-08-26 | Enzymatic RNA with activity to ras |
US98713192A | 1992-12-07 | 1992-12-07 | |
US891093A | 1993-01-19 | 1993-01-19 | |
US612293A | 1993-01-19 | 1993-01-19 | |
US07/882,822 | 1993-01-19 | ||
US07/987,131 | 1993-01-19 | ||
US08/006,122 | 1993-01-19 | ||
US07/936,531 | 1993-01-19 | ||
US07/936,532 | 1993-01-19 | ||
US08/008,910 | 1993-01-19 | ||
US07/936,422 | 1993-01-19 | ||
US07/936,421 | 1993-01-19 | ||
US07/936,110 | 1993-01-19 | ||
US07/882,885 | 1993-01-19 | ||
PCT/US1993/004573 WO1993023057A1 (fr) | 1992-05-14 | 1993-05-13 | Procede et reactif destines a empecher l'evolution du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2135499A1 true CA2135499A1 (fr) | 1993-11-25 |
Family
ID=27580619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002135499A Abandoned CA2135499A1 (fr) | 1992-05-14 | 1993-05-13 | Methode et reagent pour l'inhibition de la cancerogenese |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0641212A4 (fr) |
JP (1) | JPH08502950A (fr) |
AU (1) | AU687001B2 (fr) |
CA (1) | CA2135499A1 (fr) |
WO (1) | WO1993023057A1 (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08500481A (ja) * | 1992-05-11 | 1996-01-23 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | ウイルスの複製を阻害するための方法および薬剤 |
US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
US5834440A (en) * | 1994-03-07 | 1998-11-10 | Immusol Incorporated | Ribozyme therapy for the inhibition of restenosis |
CA2184989A1 (fr) * | 1994-03-07 | 1995-09-14 | Tsvi Goldenberg | Therapie aux ribozymes pour la restenose |
US6103890A (en) * | 1994-05-18 | 2000-08-15 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids that cleave C-fos |
US6146886A (en) | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
EP0772678A4 (fr) * | 1994-09-12 | 1999-10-20 | Hope City | Modulation de genes resistants aux rayonnements medicamenteux |
WO1996018733A2 (fr) * | 1994-12-14 | 1996-06-20 | Innovir Laboratories, Inc. | Inactivation induite par ribozyme de l'arn associe a la leucemie |
US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
EP1408111B1 (fr) | 1995-10-26 | 2010-06-09 | Sirna Therapeutics, Inc. | Procédé et réactif de traitement de maladies ou troubles liés aux niveaux du récepteur du facteur de croissance endothéliale vasculaire |
US7034009B2 (en) | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
US20020081733A1 (en) * | 1995-11-14 | 2002-06-27 | Catherine M. Verfaillie | Method to prepare drug-resistant, non-malignant hematopoietic cells |
US6238917B1 (en) * | 1996-04-02 | 2001-05-29 | Commonwealth Scientific Industrial Research Organizaion | Asymmetric hammerhead ribozymes |
CA2250857A1 (fr) * | 1996-04-02 | 1997-10-09 | Philip Hendry | Ribozymes asymetriques en forme de tete de marteau |
DE69729145T2 (de) * | 1996-05-24 | 2005-06-09 | Aventis Pharma Deutschland Gmbh | Reagenz und Verfahren zur Inhibierung der N-RAS Expression |
US7329741B2 (en) * | 1996-06-05 | 2008-02-12 | Chiron Corporation | Polynucleotides that hybridize to DP-75 and their use |
US5807743A (en) * | 1996-12-03 | 1998-09-15 | Ribozyme Pharmaceuticals, Inc. | Interleukin-2 receptor gamma-chain ribozymes |
US6057156A (en) * | 1997-01-31 | 2000-05-02 | Robozyme Pharmaceuticals, Inc. | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
US6127535A (en) | 1997-11-05 | 2000-10-03 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into oligonucleotides |
US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
US6482932B1 (en) | 1997-11-05 | 2002-11-19 | Ribozyme Pharmaceuticals, Incorporated | Nucleoside triphosphates and their incorporation into oligonucleotides |
US6995259B1 (en) | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
US6875747B1 (en) * | 1999-05-24 | 2005-04-05 | Avi Bio Pharma, Inc. | Antisense to c-myc for treatment of polycystic kidney disease |
US6607915B1 (en) * | 1999-09-30 | 2003-08-19 | Isis Pharmaceuticals, Inc. | Antisense inhibition of E2A-Pbx1 expression |
US6682902B2 (en) | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
WO2002081628A2 (fr) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation de l'expression genique associee a la proliferation inflammatoire et a la croissance de neurites, par des procedes faisant intervenir l'acide nucleique |
US7754435B2 (en) | 2000-09-21 | 2010-07-13 | Philadelphia Health And Education Corporation | Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms |
ATE369563T1 (de) * | 2000-12-28 | 2007-08-15 | Shionogi & Co | Chordin-ähnliche polypeptide und deren dns |
US7205399B1 (en) | 2001-07-06 | 2007-04-17 | Sirna Therapeutics, Inc. | Methods and reagents for oligonucleotide synthesis |
EP1375661A1 (fr) * | 2002-06-17 | 2004-01-02 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Le rôle du voie N-myc - nm23H1/nm23H2 - cdc42 dans la prolifération, le differenciation et le traitement du cancer |
JP2005529616A (ja) * | 2002-06-18 | 2005-10-06 | アイアールエム エルエルシー | 化学療法耐性腫瘍の診断および治療 |
CA2527301A1 (fr) * | 2003-05-30 | 2004-12-09 | Nippon Shinyaku Co., Ltd. | Composite contenant un acide oligonucleique et composition pharmaceutique contenant ledit composite |
EP2756845B1 (fr) * | 2009-04-03 | 2017-03-15 | Dicerna Pharmaceuticals, Inc. | Procédés et compositions pour l'inhibition spécifique de KRAS par de l'ARN double brin asymétrique |
DK2756845T3 (en) * | 2009-04-03 | 2017-06-12 | Dicerna Pharmaceuticals Inc | Methods and compositions for specific inhibition of KRAS with asymmetric double stranded RNA |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59010432D1 (de) * | 1989-03-16 | 1996-09-05 | Boehringer Ingelheim Int | Genetische Einheiten zur Inhibierung der Funktion von RNA |
US5225337A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
WO1991018625A1 (fr) * | 1990-06-07 | 1991-12-12 | City Of Hope | Inversion a mediation ribozymique de transformation par clivage de l'arn oncogene hras |
WO1991018913A1 (fr) * | 1990-06-07 | 1991-12-12 | City Of Hope | Inversion a mediation ribozymique de transformation par clivage de l'arn oncogene hras |
CA2086105A1 (fr) * | 1990-06-26 | 1991-12-27 | Premkumar Reddy | Methode de traitement de la leucemie |
-
1993
- 1993-05-13 EP EP93911311A patent/EP0641212A4/fr not_active Withdrawn
- 1993-05-13 AU AU42489/93A patent/AU687001B2/en not_active Ceased
- 1993-05-13 WO PCT/US1993/004573 patent/WO1993023057A1/fr not_active Application Discontinuation
- 1993-05-13 JP JP6500939A patent/JPH08502950A/ja active Pending
- 1993-05-13 CA CA002135499A patent/CA2135499A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0641212A1 (fr) | 1995-03-08 |
EP0641212A4 (fr) | 1997-05-21 |
AU687001B2 (en) | 1998-02-19 |
WO1993023057A1 (fr) | 1993-11-25 |
JPH08502950A (ja) | 1996-04-02 |
AU4248993A (en) | 1993-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU687001B2 (en) | Method and reagent for inhibiting cancer development | |
US5989906A (en) | Method and reagent for inhibiting P-glycoprotein (mdr-1-gene) | |
EP0786522A2 (fr) | Molécules de RNA enzymatiques pour le traitement de conditions sténotiques | |
US5750390A (en) | Method and reagent for treatment of diseases caused by expression of the bcl-2 gene | |
US5693535A (en) | HIV targeted ribozymes | |
US6017756A (en) | Method and reagent for inhibiting hepatitis B virus replication | |
EP0748383B1 (fr) | Clivage cible de l'arn par ciblage de la ribonuclease p et sequences de clivage | |
US5610054A (en) | Enzymatic RNA molecule targeted against Hepatitis C virus | |
US5616490A (en) | Ribozymes targeted to TNF-α RNA | |
WO1995004818A1 (fr) | Procede et reactif servant a inhiber la replication du virus de l'immunodeficience humaine | |
US5599704A (en) | ErbB2/neu targeted ribozymes | |
EP0728205B1 (fr) | Reactif pour le traitement d'etats arthritiques | |
US5801158A (en) | Enzymatic RNA with activity to RAS | |
US5639655A (en) | PML-RARA targeted ribozymes | |
US5622854A (en) | Method and reagent for inhibiting T-cell leukemia virus replication | |
US5714383A (en) | Method and reagent for treating chronic myelogenous leukemia | |
US6258585B1 (en) | Method and reagent for inhibiting influenza virus replication | |
WO1994029452A2 (fr) | Molecule d'arn enzymatique pour le traitement de la fibrose et de la maladie du tissu fibreux | |
US6544755B1 (en) | Method and reagent for treatment of diseases by expression of the c-Myc gene | |
AU730506B2 (en) | Method and reagent for inhibiting cancer development | |
US6492512B1 (en) | Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression | |
CA2397813A1 (fr) | Methode et reactif d'inhibition de grid | |
US20030134806A1 (en) | Method and reagent for the inhibition of grid | |
CA2168566A1 (fr) | Methode et reactif provoquant l'inhibition de la replication du virus de l'immunodeficience humaine | |
AU5661700A (en) | Method and reagent for treatment of animal diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |